SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-064815
Filing Date
2021-05-12
Accepted
2021-05-12 07:00:58
Documents
14
Period of Report
2021-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2115940d1_8k.htm   iXBRL 8-K 28440
2 EXHIBIT 99.1 tm2115940d1_ex99-1.htm EX-99.1 59655
6 GRAPHIC tm2115940d1_ex99-1img001.jpg GRAPHIC 7312
  Complete submission text file 0001104659-21-064815.txt   280516

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA zyne-20210512.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE zyne-20210512_lab.xml EX-101.LAB 34238
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zyne-20210512_pre.xml EX-101.PRE 22355
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2115940d1_8k_htm.xml XML 3615
Mailing Address 80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333
Business Address 80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333 484-581-7505
Zynerba Pharmaceuticals, Inc. (Filer) CIK: 0001621443 (see all company filings)

IRS No.: 260389433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37526 | Film No.: 21913420
SIC: 2834 Pharmaceutical Preparations